

Zack Gong

Associate



zgong@cooley.com

Life Sciences Corporate Partnering and Licensing
Life Sciences

+86 21 6030 0676

Shanghai

Zack focuses his practice on the representation of public and private pharmaceutical, biotechnology, and other life sciences companies with respect to a variety of intellectual property-based commercial transactions. He advises companies on license agreements, research collaborations and development agreements, manufacturing, distribution, and supply agreements, as well as intellectual property matters within corporate transactions such as public offerings and mergers and acquisitions.

Zack is a native Mandarin speaker and is fluent in English.

Representative Matters:

- Represented **Inmagine Biopharmaceuticals** in its successful merger with Ikena Oncology, resulting in the combined company's listing on Nasdaq, and its concurrent \$75 million PIPE financing (2025)
- Represented **Otsuka Pharmaceutical** in its exclusive global licensing agreement (excluding Greater China) with Harbour BioMed for the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager under development by Harbour BioMed (2025)
- Represented **Earendil Labs** (company affiliated with Helixon Therapeutics) in its worldwide exclusive license agreement with Sanofi for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases (2025)
- Represented **Zai Lab** in its exclusive sublicense with Zenas to develop, manufacture and commercialize Zenas' thyroid eye disease programs, including ZB001, an insulin-like growth factor-1 receptor (anti-IGF-1R) monoclonal antibody in Greater China (2025)
- Represented **Windward Bio (NewCo)** in its license agreement with Harbour BioMed and Sichuan Kelun Biotech BioPharmaceutical for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody (2025)
- Represented **Chimagen Biosciences** in its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK with US\$300 million upfront and US\$500 million development and commercial milestone payments (2024)
- Represented **Aclaris Therapeutics** in its exclusive license agreement with Biosion for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R (2024)
- Represented **Laekna** in its clinical collaboration with Eli Lilly and Company to accelerate the development of LAE102, a novel ActRIIA mAb as a treatment for obesity (2024)

- Represented a **clinical-stage biotechnology company** specializing in innovative radiopharmaceuticals in an exclusive license agreement with a leading biotechnology company granting the latter the right to commercialize the late-stage radiotherapy AlphaMedix (212Pb-DOTAMTATE) worldwide (2024)
- Represented **Instil Bio (NewCo)** in its in-licensing agreement with ImmuneOnco Biopharmaceuticals for ex-China development and commercial rights to ImmuneOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M (2024)
- Represented **Belenos Biosciences** in its exclusive license agreement with Keymed Biosciences for global research, development, registration, manufacturing and commercialization of Keymed Biosciences' drug candidates, CM512 and CM536, excluding the Greater China region (2024)
- Represented **Jiangsu Hengrui Pharmaceuticals (Hengrui)** on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco (Hercules), a newly established Delaware company (2024)
- Represented **MediLink** in its worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors (2023)
- Represented **Allay Therapeutics** in its license agreement to provide Maruishi Pharmaceutical with exclusive rights in Japan to develop and commercialize Allay's lead investigation drug candidate – ATX101 – and other ultra-sustained analgesic implantable drug candidates for acute pain (2023)
- Represented **SystImmune** in its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune's BL-B01D1 (2023)
- Represented **Rona Therapeutics** in its collaboration with Keymed Biosciences to jointly discover and develop first-in-class siRNA Therapeutics for Glomerulonephritisbinder (2023)
- Represented **JW Therapeutics** in its license and collaboration agreement with Juno Therapeutics for the research, development, manufacturing and commercialization of new cellular therapy products DLL3 in Greater China (2022)
- Represented **IASO Biotherapeutics** in an exclusive and worldwide out-licensing agreement with Cabaletta Bio (Nasdaq: CABA) to develop, manufacture and commercialize fully-human CD19 binder (2022)
- Represented **Zai Lab** (Nasdaq: ZLAB; HKEX: 9688) in its exclusive collaboration and license agreement with Seagen for the development and commercialization of TIVDAK® in Greater China (2022)
- Represented **Horizon Therapeutics** in its agreement to be acquired by Amgen at approximately \$28 billion (2022)
- Represented **Apollo Endosurgery** in its agreement to be acquired by Boston Scientific (2022)
- Represented **Sixth Street** in its strategic investment in Blueprint Medicines (2022)
- Represented **Hutchmed Limited** (Nasdaq: HCM) in its commercial license agreement with GenScript (2021)
- Represented **Hutchmed Limited** in its commercial supply and collaboration arrangement with AstraZeneca for Savolitinib in China (2021)
- Represented **Hutchmed Limited** in its technology transfer and supply agreement with Epizyme Inc. (2021)
- Represented **LianBio** (Nasdaq: LIAN) in its exclusive license agreement with MyoKardia for the rights to develop and commercialize mavacamten in Greater China and other Asian markets (2020)
- Represented **LianBio** in its strategic platform collaboration agreement with Pfizer (2020)
- Represented **CASI Pharmaceuticals, Inc.** in its license and development agreement with Cleave Therapeutics for the rights to develop and commercialize a novel VCP/p97 inhibitor in Greater China

(2020)

- Represented Janssen Biotech Inc. (J&J affiliate) in its research collaboration agreement with National University of Singapore (2020)

Education

Duke University School of Law

JD, Duke Estate Planning Council Scholarship (half-tuition), 2017

Washington University in Saint Louis

BSBA, Finance, Honors in Management, 2014

Admissions & Credentials

New York